Fractyl Health, Inc. Common Stock (GUTS)vsBeiGene, Ltd. (ONC)
GUTS
Fractyl Health, Inc. Common Stock
$0.69
-4.51%
HEALTHCARE · Cap: $122.64M
ONC
BeiGene, Ltd.
$322.08
-1.57%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 191306300% more annual revenue ($5.74B vs $3,000). ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
GUTS
Avoid18
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GUTS.
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$322.08
$1534.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GUTS
GUTS has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : GUTS
The primary concerns for GUTS are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 2.84 is elevated, increasing financial risk.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
GUTS profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
GUTS carries more volatility with a beta of 2.29 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 18/100) and 35.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fractyl Health, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company is headquartered in Lexington, Massachusetts.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?